TY - JOUR
T1 - Menopause
AU - Nelson, Heidi D.
N1 - Funding Information:
I would like to thank Sydney Edlund-Jermain for collecting articles and managing references, Andrew Hamilton for undertaking literature searches, and collaborators of previous reviews on menopause and its therapies at the Oregon Evidence-based Practice Center. This study was supported by Providence Women and Children's Health Research Center.
PY - 2008
Y1 - 2008
N2 - Menopause is the time of life when menstrual cycles cease, and is caused by reduced secretion of the ovarian hormones oestrogen and progesterone. Although menopause is a normal event for women, individual experiences vary, and some women seek medical advice for the management of symptoms. Many symptoms have been attributed to menopause, but only vasomotor dysfunction and vaginal dryness are consistently associated with this time of life in epidemiological studies. Other common symptoms such as mood changes, sleep disturbances, urinary incontinence, cognitive changes, somatic complaints, sexual dysfunction, and reduced quality of life may be secondary to other symptoms, or related to other causes. Trials of therapies for vasomotor dysfunction have shown improvements with oestrogen, gabapentin, paroxetine, and clonidine, but little or no benefit with other agents; adverse effects of these treatments must also be considered. Many questions about menopausal transition and its effects on health have not been adequately addressed.
AB - Menopause is the time of life when menstrual cycles cease, and is caused by reduced secretion of the ovarian hormones oestrogen and progesterone. Although menopause is a normal event for women, individual experiences vary, and some women seek medical advice for the management of symptoms. Many symptoms have been attributed to menopause, but only vasomotor dysfunction and vaginal dryness are consistently associated with this time of life in epidemiological studies. Other common symptoms such as mood changes, sleep disturbances, urinary incontinence, cognitive changes, somatic complaints, sexual dysfunction, and reduced quality of life may be secondary to other symptoms, or related to other causes. Trials of therapies for vasomotor dysfunction have shown improvements with oestrogen, gabapentin, paroxetine, and clonidine, but little or no benefit with other agents; adverse effects of these treatments must also be considered. Many questions about menopausal transition and its effects on health have not been adequately addressed.
UR - http://www.scopus.com/inward/record.url?scp=39649101096&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=39649101096&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(08)60346-3
DO - 10.1016/S0140-6736(08)60346-3
M3 - Review article
C2 - 18313505
AN - SCOPUS:39649101096
SN - 0140-6736
VL - 371
SP - 760
EP - 770
JO - The Lancet
JF - The Lancet
IS - 9614
ER -